X0508 4 2025-12-08 0001631574 Wave Life Sciences Ltd. WVE 0001657709 Francis Chris C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE. CAMBRIDGE MA 02138 false true false false See Remarks true Ordinary Shares 2025-12-08 4 M false 28125 3.14 A 53125 D Ordinary Shares 2025-12-08 4 S false 28125 14.50 D 25000 D Ordinary Shares 2025-12-08 4 M false 107400 3.87 A 132400 D Ordinary Shares 2025-12-08 4 S false 107400 14.556 D 25000 D Ordinary Shares 2025-12-08 4 M false 45882 4.75 A 70882 D Ordinary Shares 2025-12-08 4 S false 45882 14.5 D 25000 D Ordinary Shares 2025-12-08 4 M false 9375 3.14 A 34375 D Ordinary Shares 2025-12-08 4 S false 9375 15 D 25000 D Ordinary Shares 2025-12-08 4 M false 37500 3.14 A 62500 D Ordinary Shares 2025-12-08 4 S false 37500 14.08 D 25000 D Ordinary Shares 2025-12-08 4 M false 17900 3.87 A 42900 D Ordinary Shares 2025-12-08 4 S false 17900 15 D 25000 D Ordinary Shares 2025-12-08 4 M false 122349 4.75 A 147349 D Ordinary Shares 2025-12-08 4 S false 122349 14.195 D 25000 D Ordinary Shares 2025-12-08 4 M false 50000 10.48 A 75000 D Ordinary Shares 2025-12-08 4 S false 50000 16 D 25000 D Ordinary Shares 2025-12-08 4 M false 22500 2.83 A 47500 D Ordinary Shares 2025-12-08 4 S false 22500 14.08 D 25000 D Share Option (right to buy) 3.14 2025-12-08 4 M false 75000 0.00 D 2032-01-01 Ordinary Shares 75000 9375 D Share Option (right to buy) 3.87 2025-12-08 4 M false 125300 0.00 D 2034-02-05 Ordinary Shares 125300 161100 D Share Option (right to buy) 4.75 2025-12-08 4 M false 168231 0.00 D 2033-02-17 Ordinary Shares 168231 76469 D Share Option (right to buy) 10.48 2025-12-08 4 M false 50000 0.00 D 2031-02-01 Ordinary Shares 50000 0 D Share Option (right to buy) 2.83 2025-12-08 4 M false 22500 0.00 D 2023-07-25 Ordinary Shares 22500 0 D The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. The share option represented a right to purchase a total of 150,000 ordinary shares that vest as to 25% of the shares on January 1, 2023 and vests as to an additional 6.25% of the shares quarterly thereafter until January 1, 2026. The share option represented a right to purchase a total of 286,400 ordinary shares that vest as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.50 to $14.78 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The share option represented a right to purchase a total of 244,700 ordinary shares that vest as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.08 to $15.00 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. These share options are fully vested. SVP, Corporate Development, Head of Emerging Areas /s/ Chris Francis 2025-12-10